AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05660161 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nanofracture
Description: The planned study intervention consists of nanofracture surgical procedure for the treatment of cartilage lesions of the knee.~Nanofractures will be standardized 9 mm deep perforations in the subchondral bone.~Under arthroscopic view, the cartilage lesion is shaved to expose the margins of the lesion and remove damaged tissue. After a satisfactory lesion debridement is performed, a nanofracture device (Plasmaconcept NanoFx®) is placed through the arthroscopic portal. The awl is repeatedly penetrated through the bone until marrow elements are seen in the joint. The flow of arthroscopic fluid is interrupted to better observe the marrow elements emanating from the nanofracture holes. The distance between two consecutive perforations will be approximately 2-3 mm, and the number of perforations will depend on the cartilage lesion extension. All post-operative procedures, including the rehabilitation protocol, will be carried out according to the usual standard of care.
Study NCT05702931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 14 MG [Rybelsus]
Description: At baseline participants will initiate treatment with 3mg of oral semaglutide dosing from weeks 1 to 4. Depending on tolerability the dose will increase to 7 mg daily from weeks 5 to 8 and 14 mg from week 9. Trial medication will be dispensed to subjects for the first time immediately after randomisation and adjusted week 5 and week 9.
Study NCT05702931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT06205043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimSearch programming algorithm software
Description: This is an algorithm based method to program deep brain stimulation in patients of Parkinson's disease
Study NCT06205043 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clinician based programming
Description: This is Standard of Care programming performed for patients undergoing deep brain stimulation for Parkinson's disease
Study NCT06043505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echographic hemodynamic algorithm guiding fluid resuscitation
Description: Ultrasound Hemodynamic Algorithm (UHA):~1. st step: 1/ Assessment of left ventricular filling pressures by Mitral Doppler echocardiography (2) 2/ Pulmonary ultrasound on 4 anterior dials (3)~   E/Ea >14 and/or E/A >2~  * YES => No filling test => Bilateral anterior B lines on lung ultrasound => YES => Consider administration of diuretics~  * NO => Step 2~2. nd step: Assessment of filling response by dynamic maneuvers VTI (Velocity Time Integral) increase >15% after passive leg raising (4) or Mini-fluid challenge (5,6) Or decision of a 250ml filling test~   * YES => consider 250ml bolus filling~  * NO => stop vascular filling~3. rd step if dynamic maneuvers in favor of a response to filling: 1/ Assessment of response to 250ml filling 2/ If no response to vascular filling: Pulmonary ultrasound on 4 anterior dials (3) Change from a pulmonary profile A to a pulmonary profile B~   * YES => depletion~  * NO => stop vascular filling
Study NCT05234905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human adenovirus type 5＋Camrelizumab
Description: Recombinant human adenovirus type 5: one lesion was selected for intratumoral injection.Intratumoral injection of H101 was performed on day 1 and day 4 of each cycle, and was repeated once every 3 weeks. H101 dose:~① Tumor maximum diameter ≤5cm, 1.5×1012vp (3 injections) on day 1, 1.0×1012vp (2 injections) on day 4.~② Tumor maximum diameter >5cm but ≤10cm, 3.0×1012vp (6 injections) on day 1 and 2.0×1012vp (4 injections) on day 4.~③ Tumor maximum diameter >10cm, 4.5×1012vp (9 injections) on day 1 and 3.0×1012vp (6 injections) on day 4.~H101 intratumoral injection until the tumor is completely regressed to stop the drug, but not more than 5 cycles at most.~Camrelizumab: administered after H101 on day 1 of each cycle and repeated for 3 weeks. Camrelizumab dose: 200 mg IV.
Study NCT06343766 — intervention group
Intervention type: GENETIC
Intervention: DNA collation and genotyping
Description: DNA collation and genotyping of specific genes ENAM rs3796703, AMBN rs4694075), TUFT1 rs78802584 and KLK4 rs2242670 through PCR and sequencing for various SNPs~Dental examinations by comparing dental covariates such as the number of DMF-T index, presence of biofilm, gingivitis, fluorosis, and detection of interproximal caries with caries progression.
Study NCT06477887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Dentin Matrix
Description: Steps of Allogenic Dentin Processing:~Wash with distilled water for 30-120 minutes. Ultrasonic Cleaning Cycles: 1st with distilled water for 5-10 minutes, 2nd with 5-7% hydrogen peroxide for 10-30 minutes, then the 3rd with distilled water for 5-10 minutes at 60-80.~Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours. Demineralization with 0.5N HCL for 10-60 min. Dehydration with Neutral Ethyl Alcohol for 30 minutes, then Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours.~Wash with normal saline and freeze dry, then sterilise using ethylene oxide gas.~The extracted socket will be filled with allogenic dentin
Study NCT06477887 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous Partially Demineralized Dentine Matrix
Description: The extracted tooth will be cleaned with a diamond bur under abundant irrigation with physiological water. All filling materials (gutta-percha, composite, luting cements, etc.) will be removed with the outmost care and under magnification.~Subsequently, the tooth will be cut into fragments (5 × 5 mm) and inserted into the milling device (Tooth Transformer, Milan, Italy). According to the manufacturer, a disposable box containing disposable liquid solutions will be inserted into the device to ensure the demineralization of the graft with 0.1 M hydrochloric acid, 10% hydrogen peroxide, and demineralized water as a wash.~After 25 minutes, particle graft biomaterials will be obtained. The particle size will range from 815 µm with peaks up to 1110 µm.~The socket will be filled with the graft.
Study NCT06490484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 20mg BID
Description: Drug: HSK16149 20mg BID HSK16149 20mg, orally twice a day; treatment period: 4 weeks fixed dose.
Study NCT06490484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg BID
Description: Drug: Pregabalin 150mg BID Pregabalin 150mg, orally twice a day; treatment period: 1 week titration and 3 weeks fixed dose.
Study NCT06529107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intermittent catheterization protocol based on the best evidence
Description: A best evidence-based protocol for intermittent catheterization after radical cervical cancer surgery
Study NCT06252597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education and training
Description: education and training at a regularly scheduled occupational therapy clinic visit will be performed with handouts, verbal education, hands-on training, and video training
Study NCT05137574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Pulmonary Index (IPI) monitoring
Description: Integrated Pulmonary Index (IPI) monitor will be applied to the patients, to provide numerical data obtained from the measurements of end-tidal carbon dioxide, respiratory rate, oxygen saturation measured by pulse oximetry (SpO2), and pulse rate.
Study NCT05137574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol
Study NCT05137574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: ketamine
Study NCT05842928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARTNER intervention
Description: The PARTNER intervention includes the following components:~1. Education for health care professionals~   A) written manual on deprescribing PSA-PIM, which consists of brief information and more detailed explanations;~   B) access to digital instructional videos/podcasts that address potential problems in deprescribing and provide possible solutions;~   C) checklist for identification of drug-related problems for pharmacists;~   D) tapering support tool to facilitate the selection of tapering schemes;~   E) divisibility list for PSA-PIM to support the implementation of tapering schemes;~   F) empowerment brochures for patients each focussing on one PSA-PIM subgroup~2. Interprofessional workshop and case conference for GPs and pharmacists~3. Pharmacy visit (brown bag/medication review) including patient empowerment~4. GP practice visit including shared decision making (SDM)
Study NCT05842928 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: The control intervention only comprises a pharmacy visit with brown bag review.
Study NCT06173401 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single-fraction spine SRS
Description: Treatment Arm 1: Single-fraction spine SRS (22 Gy x 1)
Study NCT06173401 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multi-fraction spine SRS
Description: Treatment Arm 2: Multi-fraction spine SRS (14 Gy x 2)
Study NCT05475951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biomarker measurement of pannexin-1 and gasdermin-D
Description: These biomarkers were measured in the placental and adipose tissues of the participants.
Study NCT05967520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX000189
Description: JMKX000189 will be administered orally once a day
Study NCT05967520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally once a day
Study NCT05916690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy with bleomycin or cisplatin
Description: Combination of drug delivery platform (electroporation) and drug (bleomycin)
Study NCT06316427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CD7 CAR T-cell
Description: Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from patients.
Study NCT06316427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prior-HSCT donor-derived CD7 CAR T-cell
Description: Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from prior-HSCT donors.
Study NCT06316427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New donor-derived CD7 CAR T-cell
Description: Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from new donors.
Study NCT06293157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transpedicular spinal stabilization - carbon fibers-based implants
Description: Transpedicular stabilization with carbon fiber and PEEK-based implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.
Study NCT06293157 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transpedicular spinal stabilization - titanium implants
Description: Transpedicular stabilization with titanium implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.
Study NCT06293157 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transpedicular spinal stabilization - titanium implants
Description: Transpedicular stabilization with titanium implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.
Study NCT06293157 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Stereotactic body radiotherapy
Description: Spinal tumors will be treated with stereotactic body radiotherapy at a dose of 5x5 Gy (25 Gy in a total dose); either prior to or post-surgical treatment, accordingly the allocation to one of the study arms.
Study NCT06293157 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Spinal tumors will be treated with stereotactic body radiotherapy at a dose of 5x5 Gy (25 Gy in a total dose); either prior to or post-surgical treatment, accordingly the allocation to one of the study arms.
Study NCT06293157 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic body radiotherapy
Description: Spinal tumors will be treated with stereotactic body radiotherapy at a dose of 5x5 Gy (25 Gy in a total dose); either prior to or post-surgical treatment, accordingly the allocation to one of the study arms.
Study NCT05560893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relational Savoring Intervention
Description: Relational savoring (RS) involves recalling a time when one supported or comforted another person and doing so brought deep positive emotion (joy, satisfaction, love, or peace); these moments of connection in service of another are common among the CSPs who work for our community agency, but may go unnoticed in the face of the urgent stressors the COVID-19 pandemic has brought about. Prolonging and enhancing attention to these moments has the potential to both help CSPs restore regulation in the face of stress and to motivate CSPs to continue engaging in meaningful work that serves their communities.
Study NCT05560893 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relational Savoring Intervention
Description: Relational savoring (RS) involves recalling a time when one supported or comforted another person and doing so brought deep positive emotion (joy, satisfaction, love, or peace); these moments of connection in service of another are common among the CSPs who work for our community agency, but may go unnoticed in the face of the urgent stressors the COVID-19 pandemic has brought about. Prolonging and enhancing attention to these moments has the potential to both help CSPs restore regulation in the face of stress and to motivate CSPs to continue engaging in meaningful work that serves their communities.
Study NCT06258174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally.
Study NCT06446531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet administered once daily
Study NCT06446531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rybelsus Tablet
Description: Oral tablet started at a 3mg dose once daily and increased to 7mg once daily or maximum tolerable dose.
Study NCT06446531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jardiance 25Mg Tablet
Description: Oral 25 mg Sodium-Glucose Co-Transporter (SGLT2) inhibitor administered once daily
Study NCT06446531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral tablet started at a dose of 500mg with an increase of 500mg weekly up to a maximum dose of 2000mg (4 tablets)
Study NCT06446531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actos
Description: Oral tablet dosed at 15mg once daily
Study NCT05149274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012 Tablet A
Description: DWP14012 10mg
Study NCT05707429 — intervention group
Intervention type: OTHER
Intervention: The Arabic version of The International Index of Erectile Function (IIEF-5)
Description: The Arabic version of The International Index of Erectile Function A self-administered questionnaire that assesses 5 dimensions of sexual function over the most recent 4 weeks. It consists of five questions, including vaginal penetration, maintenance of erection, completion of intercourse, sexual satisfaction, and self-confidence of the patient's sexual arousal and maintenance of an erection. A total score of \< 22 is defined as ED .
Study NCT05707429 — intervention group
Intervention type: OTHER
Intervention: The Sexual Quality of Life Questionnaire Male/Female (SQoL M/F)
Description: was developed by Symonds et al.,(14) which assesses subjects' feelings toward their sexuality (ranging from 0% to 100%, with higher scores indicating higher SQoL). The SQoL M/F was developed as a condition-specific QoL questionnaire to test the relationship between sexual symptoms and other aspects of general health and sexual QoL.
Study NCT05707429 — intervention group
Intervention type: OTHER
Intervention: Assessment of depression and anxiety
Description: Arabic version of Hamilton depression and anxiety rating scale (15): used to measure the severity of anxiety and depressive symptoms, and is widely used in both clinical and research settings.
Study NCT05707429 — intervention group
Intervention type: OTHER
Intervention: The Fatigue assessment scale (16)
Description: It is a 10-item self-report scale evaluating symptoms of fatigue. The FAS treats fatigue as a unidimensional construct and does not separate its measurement into different factors. However, in order to ensure that the scale evaluates all aspects of fatigue, it measures both physical and mental symptoms. The total score ranges from 10 to 50, with a higher score indicating more severe fatigue.
Study NCT05707429 — intervention group
Intervention type: OTHER
Intervention: • Quality of life assessment
Description: Health related quality of life (HRQoL measure): using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) (17), which assesses physical, social, and emotional domains of IBD patients' lives (scores range from 10-70, with higher scores indicating better HRQoL) The SIBDQ reflects relevant clinical changes in both CD and UC.
Study NCT05707429 — intervention group
Intervention type: OTHER
Intervention: The Female Sexual Function Index (FSFI)
Description: The FSFI includes such parameters as desire, arousal, lubrication, orgasm, satisfaction, and pain. The optimal cutoff score of the FSFI is 26.55, which means that a score at or below this value is defined as female SD.
Study NCT05149274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012 Tablet B
Description: DWP14012 40mg
Study NCT05714189 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low FODMAP diet
Description: The Low FODMAP diet is an avoidance diet and consist of three phases. In the first phase, all nutrients high in FODMAPs (high-FODMAPS) are eliminated from the daily diet over a period of 2 to 6 weeks to calm down the bowel. The second phase consists of the addition of FODMAP challenges. During this phase the patient continues the Low FODMAP diet, but will reintroduce one high-FODMAP nutrient once every three days to see whether exposure to this high-FODMAP causes IBS symptoms. When this is not the case, the patient can continue eating this high-FODMAP group in their daily diet. In the third and final phase, the diet is fully personalized. This personalization is based on whether the patient tolerated the high-FODMAP nutrient or not during the FODMAP challenges. Only when the high-FODMAP nutrient is not tolerated, it is advised to permanently remove it from the daily diet.
Study NCT05714189 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Endometriosis diet
Description: The endometriosis diet The endometriosis diet is a patient experience based, avoidance diet developed by women diagnosed with endometriosis. Therefore no specific recommendations exist regarding the application of the endometriosis diet. With the endometriosis diet, women avoid nutrients they noticed provoked or aggravated their endometriosis-related symptoms such as red meat, coffee, sugar, lactose and soy.
Study NCT05991154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Practice + JoyPop
Description: Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
Study NCT05083247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFIRINOX or Gemcitabine nab-paclitaxel
Description: oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV OR Gemcitabine IV Nab paclitaxel
Study NCT05083247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX or Gemcitabine nab-paclitaxel
Description: oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV OR Gemcitabine IV Nab paclitaxel
Study NCT05083247 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Isotoxic High-Dose (iHD)-SBRT
Description: Radiation therapy
Study NCT05083247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery
Study NCT05083247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study NCT05970861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried Mare Milk (Saumal)
Description: Freeze-dried Mare Milk (Saumal) is frequently reported for having therapeutic and dietary properties associated with specific chemical composition and certain physical properties of the product. It contains a total of about 40 biologically active components, the most important of them vitamins A, C, B1, B2, B6, and B12, amino acids, enzymes, and trace elements (low molecular weight peptides, lactalbumins, and globulins). Saumal will be administered to patients at a dose of 25 grams of dry powder per 200 ml of water, 2 times a day, 30 minutes before the meal, for 4 weeks.
Study NCT06585969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Description: Trastuzumab deruxtexan every three weeks
Study NCT06585969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribociclib with ET
Description: Ribociclib with endocrine therapy
Study NCT06585969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib with ET
Description: Abemaciclib with endocrine therapy
Study NCT06656299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided external oblique intercostal plane block
Description: ultrasound guided external oblique intercostal plane block